| Overall (N = 3972) | Survivors (N = 3747) | Non-survivors (N = 225) | P-value |
---|---|---|---|---|
Age, years | 59.0 ± 11.9 | 58.4 ± 11.8 | 68.4 ± 10.6 | < 0.001 |
Male sex, n (%) | 3132 (78.8) | 2993 (79.9) | 139 (61.8) | < 0.001 |
Diabetes mellitus, n (%) | 1299 (32.7) | 1207 (32.2) | 92 (40.9) | 0.007 |
Hypertension, n (%) | 2429 (61.2) | 2262 (60.4) | 167 (74.2) | < 0.001 |
Peripheral artery diseases, n (%) | 159 (4.0) | 141 (3.8) | 18 (8.0) | 0.002 |
Previous CABG or PCI, n (%) | 583 (14.7) | 548 (14.6) | 35 (15.6) | 0.702 |
STEMI, n (%) | 3467 (87.3) | 3269 (87.2) | 198 (88.0) | 0.741 |
Tumor diseases, n (%) | 81 (2.0) | 71 (1.9) | 10 (4.4) | 0.009 |
Liver diseases, n (%) | 570 (14.8) | 555 (14.8) | 15 (6.7) | 0.001 |
COPD, n (%) | 32 (0.8) | 27 (0.7) | 5 (2.2) | 0.014 |
Hemodynamics | Â | Â | Â | Â |
Heart rate, bpm | 77.4 ± 15.2 | 77.0 ± 14.9 | 83.4 ± 19.7 | < 0.001 |
Systolic blood pressure, mmHg | 124.7 ± 18.3 | 124.8 ± 18.1 | 123.0 ± 21.9 | 0.157 |
EF, % | 53.8 ± 7.6 | 54.1 ± 7.4 | 48.6 ± 9.2 | < 0.001 |
Cardiac arrest, n (%) | 144 (3.6) | 125 (3.3) | 19 (8.4) | < 0.001 |
Laboratory tests | Â | Â | Â | Â |
D-dimer, ng/mL | 330 (220–590) | 330 (220–550) | 600 (320–1240) | < 0.001 |
LDL-C, mmol/L | 2.7 ± 0.9 | 2.7 ± 0.9 | 2.7 ± 0.9 | 0.331 |
hsCRP, mg/L | 7.16 (2.75–12.03) | 7.00 (2.71–11.94) | 11.17 (3.88–13.13) | < 0.001 |
Creatinine, µmoI/L | 82.0 ± 25.1 | 81.0 ± 22.8 | 98.1 ± 47.1 | < 0.001 |
Peak cTnI, ng/mL | 2.50 (0.44–10.80) | 2.48 (0.44–10.62) | 2.97 (0.62–14.01) | 0.093 |
GRACE score | 109.7 ± 27.7 | 107.7 ± 25.9 | 142.0 ± 35.0 | < 0.001 |
TIMI score | 6.3 ± 1.8 | 6.2 ± 1.8 | 8.0 ± 2.0 | < 0.001 |
Findings and details of PCI procedures | ||||
Culprit lesion, n (%) | Â | Â | Â | Â |
Left main artery | 95 (2.4) | 80 (2.1) | 15 (6.7) | < 0.001 |
Left anterior descending artery | 1734 (43.7) | 1632 (43.6) | 102 (45.3) | Â |
Left circumflex | 610 (15.4) | 592 (15.8) | 18 (8.0) | Â |
Right coronary artery | 1515 (38.1) | 1429 (38.1) | 86 (38.2) | Â |
Bypass graft | 18 (0.5) | 14 (0.4) | 4 (1.8) | Â |
Multi-vessel disease, n (%) | Â | Â | Â | Â |
1-vessel disease | 1002 (25.2) | 966 (25.8) | 36 (16.0) | < 0.001 |
2-vessel disease | 1253 (31.6) | 1201 (32.1) | 52 (23.1) | Â |
3-vessel disease | 1717 (43.2) | 1580 (42.2) | 137 (60.9) | Â |
Pre-PCI TIMI 0 flow, n (%) | 2607 (65.6) | 2441 (65.2) | 166 (73.8) | 0.008 |
Post-PCI TIMI 3 flow, n (%) | 3822 (96.2) | 3617 (96.5) | 205 (91.1) | < 0.001 |
D2B time, mins | 128 (95–202) | 128 (95–201) | 125 (90–219) | 0.342 |
Stent placements, n (%) | 3497 (88.0) | 3321 (88.6) | 176 (78.2) | < 0.001 |
Thrombus aspiration, n (%) | 1649 (41.5) | 1561 (41.7) | 88 (39.1) | 0.451 |
IABP, n (%) | 381 (9.6) | 323 (8.6) | 58 (25.8) | < 0.001 |
Glycoprotein IIb/IIIa inhibitor, n (%) | 534 (13.4) | 507 (13.5) | 27 (12.0) | 0.513 |
Complete revascularization before discharge, n (%) | 1731 (43.6) | 1669 (44.5) | 62 (27.6) | < 0.001 |
Medications a | Â | Â | Â | Â |
Aspirin, n (%) | 3930 (98.9) | 3718 (99.2) | 212 (94.2) | < 0.001 |
P2Y12 inhibitors, n (%) | 3936 (99.1) | 3719 (99.3) | 217 (96.4) | < 0.001 |
Statins, n (%) | 3708 (93.4) | 3507 (93.6) | 201 (89.3) | 0.013 |